Clinical Trials on Myelodysplasia

Total 2426 results

Massachusetts General Hospital
Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Brigham and...

Terminated

Study of Velcade and Thalidomide in Patients With Myelodysplasia

Myelodysplastic Syndrome

United States
Karolinska University Hospital
Nordic MDS Group

Recruiting

A Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDS

Myelodysplastic Syndromes | Acute Myeloid Leukemia With Myelodysplasia Related Disease and < 30% Blasts | Mixed Myelodysplastic/Myeloproliferative Disease

Sweden
University Hospital, Grenoble
Novartis

Completed

Evaluating Low-dose Deferasirox (DFX) in Patients With Low-risk MDS Resistant or Relapsing After ESA Agents (LODEFI)

Myelodysplasia

France
Massachusetts General Hospital
Dana-Farber Cancer Institute; Celgene Corporation

Completed

A Phase 1 Dose Escalating Trial of Bortezomib in Combination With Lenalidomide in Patients With Myelodysplasia

Myelodysplasia

United States
Peter MacCallum Cancer Centre, Australia
Celgene Corporation

Unknown

Lenalidomide and Recombinant Human Stem Cell Factor for Treatment of Myelodysplasia

Myelodysplasia

Australia
Saint-Louis Hospital, Paris, France
University Hospital, Clermont-Ferrand; University Hospital, Grenoble; Hospital...

Completed

Allogeneic Hematopoietic Stem Cell Transplantation Evaluation in High Risk Myelodysplasia: an Observational Non-interventional Study (ONIalloMDS)

Myelodysplasia

France
Merck Sharp & Dohme LLC

Terminated

Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED)

Myelodysplastic Syndromes | Leukemia, Myelomonocytic, Chronic | Myelodysplasia | Myelomonocytic
Sherif Farag

Withdrawn

Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk Myelodysplasia

Aml | AML, Adult
Sidney Kimmel Comprehensive Cancer Center at Johns...
Pfizer; The Leukemia and Lymphoma Society

Terminated

A Phase 1 Trial of TST of PD 0332991 Followed by Cytarabine and Mitoxantrone for Adults With Relapsed and Refractory Acute Leukemias and High-Risk Myelodysplasia

Refractory Acute Leukemia | Relapsed Acute Leukemia | High-Risk Myelodysplasia

United States
Brown University
Memorial Hospital of Rhode Island; Roger Williams Medical Center

Terminated

Decitabine, Cytarabine, GCSF for Refractory AML/MDS

Leukemia | Myelodysplasia

United States
University of Southern California
National Cancer Institute (NCI)

Active, not recruiting

Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Therapy-Related Acute Myeloid Leukemia | Acute Myeloid Leukemia With Myelodysplasia-Related Changes

United States
National Cancer Institute (NCI)

Recruiting

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm | Acute Myeloid Leukemia Post Cytotoxic Therapy | Acute Myeloid Leukemia, Myelodysplasia-Related

United States, Puerto Rico, Canada
National Cancer Institute (NCI)

Active, not recruiting

Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia

Previously Treated Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome | Secondary Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia,...

United States
Sunnybrook Health Sciences Centre
Queen's University; Ontario Molecular Pathology Research Network

Unknown

Mutational Analysis as a Prognostic and Predictive Marker of Cardiovascular (CVD) Disease in Patients With Myelodysplasia

Cardiovascular Diseases | Inflammation | MDS

Canada
Jazz Pharmaceuticals

Completed

A Post-Marketing Observational Study of VYXEOS™

Therapy-Related Acute Myeloid Leukemia | Acute Myeloid Leukemia With Myelodysplasia-Related Changes

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Active, not recruiting

Collecting and Storing Blood, Bone Marrow, and Other Samples From Patients With Acute Leukemia, Chronic Leukemia, or Myelodysplastic Syndromes

Acute Leukemia | Myelodysplasia | Chronic Leukemia

United States
Nationwide Children's Hospital

Active, not recruiting

Haploidentical Hematopoietic Cell Transplantation for Children With Hematologic Malignancies and Myelodysplasia

Hematologic Malignancy | Myelodysplasia

United States
University of Florida
Hyundai Hope On Wheels

Completed

Phase I, Dose Escalation Study of Decitabine

Leukemia, Lymphoblastic, Acute | Leukemia, Myeloid Acute | Hematopoetic Myelodysplasia

United States
Jazz Pharmaceuticals
Advice Pharma S.r.l.

Active, not recruiting

VYxeoS Liposomal Italian Observational Study iN the Real Practice (VYSION)

Acute Myeloid Leukemia (AML) | Therapy-Related Acute Myeloid Leukemia | Acute Myeloid Leukemia With Myelodysplasia-Related Changes

Italy
Fondazione Italiana Sindromi Mielodisplastiche-ETS

Completed

Identification of Mechanism in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation Therapy (BIOFER12)

Myelofibrosis | Aplastic Anemia | Myelodysplasia

Italy
University of Southern California
National Cancer Institute (NCI)

Terminated

Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes | Recurrent Adult Acute Myeloid Leukemia

United States
Aptose Biosciences Inc.

Terminated

A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS

Acute Myelogenous Leukemia | Acute Myelogenous Leukemia in Relapse | Acute Myelogenous Leukemia, Relapsed, Adult | Acute Myelogenous Leukemia, Adult | High Risk Myelodysplasia

United States
University of Southern California
National Cancer Institute (NCI); Van Andel Research Institute

Active, not recruiting

Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed

Chronic Myelomonocytic Leukemia | Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes | Myelodysplastic Syndrome

United States
Children's Hospital of Philadelphia

Active, not recruiting

Allogeneic Stem Cell Transplant With Alpha/Beta T AND B Cell Depletion for Hematologic Malignancies (AB-CliniMACs)

Lymphoma | Leukemia | Myelodysplasia

United States
Roswell Park Cancer Institute
Jazz Pharmaceuticals

Recruiting

CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Acute Myeloid Leukemia With Myelodysplasia-Related Changes

United States
David Rizzieri, MD
Miltenyi Biomedicine GmbH

Completed

Allo Non-myeloablative SCT Utilizing Matched Family Member Stem Cells Purged Using Campath

Lymphoma | Leukemia | Solid Tumors | Myelodysplasia | Myeloma

United States
M.D. Anderson Cancer Center
MDS Clinical Research Consortium

Completed

Interventional Validation of an MDS-Specific Measure of Quality of Life: Assessing the Responsiveness of the Quality of Life in Myelodysplasia Scale (QUALMS-1) to Different Hypomethylating Agent Regimens for Low and Intermediate Risk Disease

Leukemia

United States
David Rizzieri, MD
Miltenyi Biomedicine GmbH

Completed

Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath

Lymphoma | Leukemia | Solid Tumors | Myelodysplasia | Myeloma

United States
University of California, San Francisco

Completed

Unrelated Stem Cell Transplantation for Adults With Hematopoietic Disorders

Lymphoma | Myeloproliferative Disorders | AML | Myelodysplasia | CML | ALL

United States
National Heart, Lung, and Blood Institute (NHLBI)
National Cancer Institute (NCI); Blood and Marrow Transplant Clinical Trials...

Completed

Calcineurin Inhibitor-Free Interventions BMT CTN 1301 for Prevention of Graft-versus-Host Disease (BMT CTN 1301)

Acute Leukemia | Myelodysplasia

United States
Ciusss de L'Est de l'Île de Montréal
ExCellThera inc.; Stem Cell Network

Active, not recruiting

UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia

Cord Blood Transplant | High Risk Hematologic Malignancy

Canada
ExCellThera inc.
Fred Hutchinson Cancer Center

Active, not recruiting

US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia

High Risk Hematological Malignancy | Cord Blood Transplant

United States, Netherlands
Fondazione Policlinico Universitario Agostino Gemelli...
Ministry of Health, Italy

Terminated

Haploidentical Stem Cell Transplant With or Without NK Cell Infusion in AML and MDS (Bigeminy)

Acute Myeloid Leukemia | Myelodysplasia

Italy
Dana-Farber Cancer Institute
Brigham and Women's Hospital

Completed

Study of Vaccination With Autologous Acute Myeloblastic Leukemia Cells in Patients With Advanced Myelodysplasia or Acute Myelogenous Leukemia

Acute Myelogenous Leukemia | Myelodysplasia

United States
University of Birmingham

Active, not recruiting

Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCT (AMADEUS)

Acute Myeloid Leukemia | Myelodysplasia

United Kingdom
Magenta Therapeutics, Inc.

Terminated

Study of MGTA-117 in Patients With Adult Acute Myeloid Leukemia (AML) and Myelodysplasia-Excess Blasts (MDS-EB)

Acute Myeloid Leukemia | Myelodysplasia

United States
CASI Pharmaceuticals, Inc.

Completed

A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies

Myelodysplasia | Hematological Malignancies | Agnogenic Myeloid Metaplasia

Canada
University Hospital Southampton NHS Foundation...
Genzyme, a Sanofi Company

Completed

Clofarabine Pre-conditioning With Allogeneic Transplant for Acute Myeloid Leukaemia (AML)

Myelodysplasia | Acute Myeloid Leukaemia

United Kingdom
St. Jude Children's Research Hospital
National Cancer Institute (NCI)

Completed

Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia

Leukemia, Myelocytic, Acute

United States
McMaster University
Sanofi; Ozmosis Research Inc.; Cell Therapy Transplant Canada

Recruiting

ATG Plus PTCy vs ATG for CGVHD Prophylaxis

Acute Leukemia | Myelodysplasia | Chronic Graft-versus-host-disease

Canada, Australia
Virginia Commonwealth University

Completed

Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients

Myeloid Leukemia | Myelodysplasia | Lymphoid Leukemia | Monocytic Leukemia

United States
Brian Jonas
National Cancer Institute (NCI); Celgene; Pharmacyclics LLC.

Completed

Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome

Previously Treated Myelodysplastic Syndrome | Myelodysplastic Syndrome | Therapy-Related Myelodysplastic Syndrome | Secondary Myelodysplastic Syndrome | Refractory High Risk Myelodysplastic Syndrome

United States
M.D. Anderson Cancer Center

Withdrawn

Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms

Myeloproliferative Neoplasm | Myelodysplastic Neoplasm | Pathway Mutant Myelodysplastic Syndromes

United States
University of Utah

Completed

Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies

Lymphoma | Leukemia | Chronic Disease | Myelodysplasia | Acute Leukaemia

United States
Wyeth is now a wholly owned subsidiary of Pfizer
PETHEMA (Program for the Study and Treatment of Haematological Malignances)

Completed

Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients

Lymphoma | Leukemia | Stem Cell Transplantation | Myelodysplasia | Myeloma | Hematological Malignancy

Spain
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Azacitidine and Etanercept in Treating Patients With Myelodysplastic Syndromes

Previously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | de Novo Myelodysplastic Syndromes

United States
BeiGene

Recruiting

A Study of BGB-11417 in Participants With Myeloid Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Myelodysplastic/Myeloproliferative Neoplasm

China, France, Australia, Germany, Spain, Korea, Republic of, New Zealand, Italy, United Kingdom, United States
David Rizzieri, MD

Completed

Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant

Leukemia | Myelodysplasia | Myeloma | Non Hodgkin's Lymphoma | Hodgkin's Disease

United States
Duke University

Completed

Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants

Lymphoma | Leukemia | Myelofibrosis | Solid Tumors | Myelodysplasia | Myeloma | Hodgkin's Disease

United States
National Cancer Institute (NCI)

Completed

Belinostat in Treating Patients With Myelodysplastic Syndromes

Previously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | de Novo Myelodysplastic Syndromes

United States

Clinical Trials on Myelodysplasia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Thailand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations